<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39369180</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1432-0851</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>12</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>Cancer immunology, immunotherapy : CII</Title><ISOAbbreviation>Cancer Immunol Immunother</ISOAbbreviation></Journal><ArticleTitle>Increased myositis and possible myocarditis in melanoma patients treated with immune checkpoint inhibitors in the COVID-19 era.</ArticleTitle><Pagination><StartPage>259</StartPage><MedlinePgn>259</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">259</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00262-024-03803-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Immune checkpoint inhibitor (ICI)-mediated myocarditis results in significant morbidity and mortality. At our institution, we noted an increased incidence of ICI-mediated myocarditis cases, leading to further investigation in our database of advanced melanoma patients treated with ICI therapy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A single-center, retrospective cohort analysis of patients with advanced melanoma identified cases of ICI-mediated myocarditis and myositis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">366 patients with advanced melanoma received a dose of ICI from September 2014 to October 2019. Of these patients, there were 0 cases of ICI-mediated myocarditis (0%, 95% CI 0%-1.0%) and 2 cases of ICI-mediated myositis (0.55%, 95% CI 0.07%-1.96%). From November 2019 to December 2021, an additional 246 patients with advanced melanoma were identified. Of these patients, 10 (4.1%, 95% CI 1.97%-7.35%) developed ICI-mediated myocarditis and 10 developed ICI-mediated myositis.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our study suggests an increase in prevalence of ICI-mediated muscle damage including myositis and myocarditis in the COVID-19 era. Differentiation of these patients and further risk stratification may allow for development of guidelines for nuanced management of this serious complication.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gradone</LastName><ForeName>Allison L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. alg021@jefferson.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA. alg021@jefferson.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Vincent T</ForeName><Initials>VT</Initials><AffiliationInfo><Affiliation>Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Hematology, Medical Oncology, and Palliative Care, Department of Internal Medicine, University of Wisconsin, Madison, WI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, University of Wisconsin, Madison, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasbinder</LastName><ForeName>Alexi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fecher</LastName><ForeName>Leslie A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yentz</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayek</LastName><ForeName>Salim S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lao</LastName><ForeName>Christopher D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Cancer Immunol Immunother</MedlineTA><NlmUniqueID>8605732</NlmUniqueID><ISSNLinking>0340-7004</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008545" MajorTopicYN="Y">Melanoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000082082" MajorTopicYN="Y">Immune Checkpoint Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="Y">Myocarditis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009220" MajorTopicYN="Y">Myositis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Immunotherapy</Keyword><Keyword MajorTopicYN="N">Melanoma</Keyword><Keyword MajorTopicYN="N">Myocarditis</Keyword><Keyword MajorTopicYN="N">Myositis</Keyword></KeywordList><CoiStatement>VTM serves as a consulting or advisory role for Immunocore, Regeneron, Bristol Myers Squibb, Incyte, Replimune, and Partner Therapeutics. CL receives clinical trial funding from BMS, Novartis and is currently employed by BMS. LF receives clinical trial funding from BMS, Kartos, Array/Pfizer, Merck, Pfizer/EMD Serono and serves as a consultant for Elsevier. AG, AV, SY, SH have no conflicts of interest</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>5</Day><Hour>23</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39369180</ArticleId><ArticleId IdType="pmc">PMC11456101</ArticleId><ArticleId IdType="doi">10.1007/s00262-024-03803-5</ArticleId><ArticleId IdType="pii">10.1007/s00262-024-03803-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381(16):1535–1546. 10.1056/NEJMoa1910836</Citation><ArticleIdList><ArticleId IdType="pubmed">31562797</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A (2015) KEYNOTE-006 investigators. pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26):2521–2532. 10.1056/NEJMoa1503093</Citation><ArticleIdList><ArticleId IdType="pubmed">25891173</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang DY, Salem J, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4(12):1721–1728. 10.1001/jamaoncol.2018.3923</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6440712</ArticleId><ArticleId IdType="pubmed">30242316</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasbinder A, Chen Y, Procureur A et al (2022) Biomarker trends, incidence, and outcomes of immune checkpoint inhibitor-induced myocarditis. JACC Cardio Oncol 4(5):689–700. 10.1016/j.jaccao.2022.11.004</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9830199</ArticleId><ArticleId IdType="pubmed">36636441</ArticleId></ArticleIdList></Reference><Reference><Citation>Salem JE, Manouchehri A, Moey M et al (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19(12):1579–1589. 10.1016/S1470-2045(18)30608-9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6287923</ArticleId><ArticleId IdType="pubmed">30442497</ArticleId></ArticleIdList></Reference><Reference><Citation>Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB (2018) Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391(10124):933. 10.1016/S0140-6736(18)30533-6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6668330</ArticleId><ArticleId IdType="pubmed">29536852</ArticleId></ArticleIdList></Reference><Reference><Citation>Makunts T, Saunders IM, Cohen IV et al (2021) Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. Sci Rep 11:17324. 10.1038/s41598-021-96467-5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8405813</ArticleId><ArticleId IdType="pubmed">34462476</ArticleId></ArticleIdList></Reference><Reference><Citation>Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A (2020) Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc 9(2):e013757. 10.1161/JAHA.119.013757</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7033840</ArticleId><ArticleId IdType="pubmed">31960755</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39(36):4073–4126. 10.1200/JCO.21.01440</Citation><ArticleIdList><ArticleId IdType="pubmed">34724392</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaca MP, Olenchock BA, Salem JE et al (2019) Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation 140(2):80–91. 10.1161/CIRCULATIONAHA.118.034497</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6779326</ArticleId><ArticleId IdType="pubmed">31390169</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kindi SG, Oliveira GH (2018) Reporting of immune checkpoint inhibitor-associated myocarditis. Lancet 392(10145):382–383. 10.1016/S0140-6736(18)31542-3</Citation><ArticleIdList><ArticleId IdType="pubmed">30102167</ArticleId></ArticleIdList></Reference><Reference><Citation>de Du Fay Lavallaz J, Prepoudis A, Wendebourg MJ et al (2022) Skeletal muscle disorders: a noncardiac source of cardiac troponin T. Circulation 145(24):1764–1779. 10.1161/CIRCULATIONAHA.121.058489</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10069758</ArticleId><ArticleId IdType="pubmed">35389756</ArticleId></ArticleIdList></Reference><Reference><Citation>Lie G, Weickhardt A, Kearney L et al (2020) Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma case report. Trans Lung Cancer Res. 10.21037/tlcr.2020.02.0</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7225145</ArticleId><ArticleId IdType="pubmed">32420076</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried JA, Ramasubbu K, Bhatt R et al (2020) The variety of cardiovascular presentations of COVID-19. Circulation 141(23):1930–1936. 10.1161/CIRCULATIONAHA.120.047164</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314498</ArticleId><ArticleId IdType="pubmed">32243205</ArticleId></ArticleIdList></Reference><Reference><Citation>Witberg G, Barda N, Hoss S et al (2021) Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med 385(23):2132–2139. 10.1056/NEJMoa2110737</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8531986</ArticleId><ArticleId IdType="pubmed">34614329</ArticleId></ArticleIdList></Reference><Reference><Citation>Barda N, Dagan N, Ben-Shlomo Y et al (2021) Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med 385(12):1078–1090. 10.1056/NEJMoa2110475</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8427535</ArticleId><ArticleId IdType="pubmed">34432976</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehmer TK, Kompaniyets L, Lavery AM et al (2021) Association between COVID-19 and myocarditis using hospital-based administrative data—United States march 2020–january 2021. MMWR Morb Mortal Wkly Rep 70:1228–1232. 10.15585/mmwr.mm7035e5external</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8422872</ArticleId><ArticleId IdType="pubmed">34473684</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniels CJ, Rajpal S, Greenshields JT et al (2021) Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the big ten COVID-19 cardiac registry. JAMA Cardiol 6(9):1078–1087. 10.1001/jamacardio.2021.2065</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8160916</ArticleId><ArticleId IdType="pubmed">34042947</ArticleId></ArticleIdList></Reference><Reference><Citation>Seko Y, Yagita H, Okumura K, Azuma M, Nagai R (2007) Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3. Cardiovasc Res 75(1):158–167. 10.1016/j.cardiores.2007.03.012</Citation><ArticleIdList><ArticleId IdType="pubmed">17434153</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>